Zovegalisib Breakthrough: A Mid-Term Long Trade on Relay (RLAY) Backed by Regulatory Momentum
Relay Therapeutics' zovegalisib just cleared a major regulatory hurdle with FDA Breakthrough Therapy designation, validating clinical benefit signals and compressing timelines. With a market cap around $1.82B, bullish technicals and heavy short interest, this is a high-reward, high-risk mid-term trade aiming to capture a re-rating on upcoming data …